L’Oréal acquired a minority stake in Timeline, a Swiss longevity biotech company. The terms of this deal, facilitated through L’Oréal’s strategic venture capital fund, BOLD, have not been publicly disclosed.
Timeline, which originated as a spinoff from the Swiss Federal Institute of Technology in 2007, has been at the forefront of developing solutions for longevity in various sectors, including food, business, and health. The company’s president, Chris Rinsch, and chairman, Patrick Aebischer, have spearheaded its mission. L’Oréal highlighted that Timeline has successfully created a proprietary molecule called Mitopure, which plays a vital role in recycling and rejuvenating aging mitochondria, the powerhouses of cells. This groundbreaking technology has been backed by over a decade of rigorous scientific research, multiple gold standard clinical studies, and an extensive intellectual property portfolio.
Through its investment in Timeline, L’Oréal aims to support the further development of this unique technology and expand the company’s operations. Additionally, this partnership opens doors for future collaborations between L’Oréal and Timeline. The beauty industry has been evolving rapidly, and the focus has shifted towards the convergence of health, well-being, and scientific advancements. The concept of longevity has emerged as a key talking point and a transformative force in the market.
Barbara Lavernos, the deputy CEO of L’Oréal responsible for research, innovation, and technology, emphasized that L’Oréal has been actively studying and anticipating the implications of longevity for beauty for more than a decade. She expressed excitement about the potential of transposing the fundamental principles of longevity onto skin health and beauty through their investment in Timeline.
Patrick Aebischer, Chairman of Timeline, emphasized that this strategic collaboration reflects their belief in a multidimensional approach to drive meaningful advancements in longevity and health span.
